Giuseppe
Emeritus
Advanced antisense therapies for postexposure protection against lethal filovirus infections (Nature Medicine, abstract, edited)
[Source: Nature Medicine, summary: <cite cite="http://www.nature.com/nm/journal/v16/n9/full/nm.2202.html">Access : Advanced antisense therapies for postexposure protection against lethal filovirus infections : Nature Medicine</cite>. Extract, edited.]
Brief Communication
Nature Medicine 16, 991 - 994 (2010)
Published online: 22 August 2010 | doi:10.1038/nm.2202
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Travis K Warren 1,4, Kelly L Warfield 1,3,4, Jay Wells 1, Dana L Swenson 1,3, Kelly S Donner 1, Sean A Van Tongeren 1, Nicole L Garza 1, Lian Dong 1, Dan V Mourich 2, Stacy Crumley 2, Donald K Nichols 1, Patrick L Iversen 2 & Sina Bavari 1
Abstract
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30?60 min after infection, protects >60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
-
------<cite cite="http://www.nature.com/nm/journal/v16/n9/full/nm.2202.html"></cite>
[Source: Nature Medicine, summary: <cite cite="http://www.nature.com/nm/journal/v16/n9/full/nm.2202.html">Access : Advanced antisense therapies for postexposure protection against lethal filovirus infections : Nature Medicine</cite>. Extract, edited.]
Brief Communication
Nature Medicine 16, 991 - 994 (2010)
Published online: 22 August 2010 | doi:10.1038/nm.2202
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Travis K Warren 1,4, Kelly L Warfield 1,3,4, Jay Wells 1, Dana L Swenson 1,3, Kelly S Donner 1, Sean A Van Tongeren 1, Nicole L Garza 1, Lian Dong 1, Dan V Mourich 2, Stacy Crumley 2, Donald K Nichols 1, Patrick L Iversen 2 & Sina Bavari 1
Abstract
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30?60 min after infection, protects >60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
-
------<cite cite="http://www.nature.com/nm/journal/v16/n9/full/nm.2202.html"></cite>